=>
Uploading C:\Program Files\Stnexp\Queries\10622320.str



chain nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 16 17 18 19 20 21 22 23 25 26 27 28 29 30
chain bonds :
1-2 1-6 2-3 2-8 3-4 3-5 6-7 10-11 12-14 13-15 16-18 17-20 18-19 18-22 20-21 20-23 25-27 25-29 26-28 26-30
exact/norm bonds :
1-2 1-6 2-8 3-4 3-5 6-7 10-11 12-14 13-15 16-18 17-20 18-19 18-22 20-21 20-23 25-27 25-29 26-28 26-30
exact bonds :
2-3

G1:C,S

G2:O,N

G3:C,O,S,N,SO2,[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14]

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS

```
Generic attributes :
1:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Number of Hetero Atoms  : less than 2
Type of Ring System     : Monocyclic
7:
Saturation              : Unsaturated
8:
Saturation              : Unsaturated

Element Count :
Node 1: Limited
    C,C5
    N,N1
    O,O0
    S,S0



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:38:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 318199 TO ITERATE

  0.6% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      6331445 TO  6396515
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10622320 (a).str
```



chain nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 16 17 18 19 21 22 23 24 25 26
ring nodes :
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 69 70 71 72 73 74 76 77 78 79 80 81
chain bonds :
1-2 1-6 2-3 2-8 3-4 3-5 6-7 10-11 12-14 13-16 14-15 14-18 16-17 16-19 21-23 21-25 22-24 22-26
ring bonds :
41-42 41-46 42-43 43-44 44-45 45-46 47-48 47-52 48-49 49-50 50-51 51-52 53-54 53-58 54-55 55-56 56-57 57-58 69-70 69-74 70-71 71-72 72-73 73-74 76-77 76-81 77-78 78-79 79-80 80-81
exact/norm bonds :
1-2 1-6 2-8 3-4 3-5 6-7 10-11 12-14 13-16 14-15 14-18 16-17 16-19 21-23 21-25 22-24 22-26

```
exact bonds :
2-3
normalized bonds :
41-42  41-46  42-43  43-44  44-45  45-46  47-48  47-52  48-49  49-50  50-51  51-52
53-54  53-58  54-55  55-56  56-57  57-58  69-70  69-74  70-71  71-72  72-73  73-74
76-77  76-81  77-78  78-79  79-80  80-81
isolated ring systems :
containing 41 : 47 : 53 : 69 : 76 :


G1:C,S

G2:O,N

G3:C,O,S,N,SO2,[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10]

G4:[*11-*12],[*13-*14],[*15-*16],[*17-*18],[*19-*20]

Match level :
1:Atom  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:Atom  8:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  41:Atom
42:Atom  43:Atom  44:Atom  45:Atom  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom
51:Atom  52:Atom  53:Atom  54:Atom  55:Atom  56:Atom  57:Atom  58:Atom  69:Atom
70:Atom  71:Atom  72:Atom  73:Atom  74:Atom  76:Atom  77:Atom  78:Atom  79:Atom
80:Atom  81:Atom
Generic attributes :
7:
Saturation              : Unsaturated
8:
Saturation              : Unsaturated

Element Count :
Node 1: Limited
    C,C5
    N,N1
    O,O0
    S,S0




L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam
SAMPLE SEARCH INITIATED 16:47:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1379 TO ITERATE
```

```
100.0% PROCESSED     1379 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        25353 TO    29807
PROJECTED ANSWERS:               6 TO      266

L4            6 SEA SSS SAM L3

=> => s l3 sss ful
FULL SEARCH INITIATED 16:48:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  26958 TO ITERATE

100.0% PROCESSED    26958 ITERATIONS                                97 ANSWERS
SEARCH TIME: 00.00.01

L5           97 SEA SSS FUL L3

=> => s l5
L6            6 L5

=> d l6 1-6 bib,ab,hitstr
```

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:632264 CAPLUS
DN 143:146724
TI Thienopyridine compounds as IκB kinase inhibitors
IN Horiguchi, Yoshiaki; Matsumoto, Takahiro; Hosono, Hiroshi; Kawamoto, Tomohiro
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 122 pp.
CODEN: JKXXAF
DT Patent
LA Japanese

not prior

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005194198	A2	20050721	JP 2003-435023	20031226
PRAI JP 2003-435023		20031226		

AB The invention provides thienopyridine compds. I (R1, R2, R3, R4 = H, substituent; R5 = substituent) or their salts or prodrugs as IκB kinase inhibitors for treatment of diabetes and related disease. For example, 3-amino-6-(4-aminopiperidin-1-yl)-4-(2-furyl)thieno[2,3-b]pyridine-2-carboxamide was prepared, and examined for its inhibitory effect on IκB kinase, TNFα, and NHκB transcription in vitro. Also, a capsule containing 3-amino-4-(3-furyl)6-piperidin-1-ylthieno[2,3-b]pyridine-2-carboxamide 30 mg/capsule was formulated.

IT **858644-13-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridine compds. as IB kinase inhibitors)

RN 858644-13-0 CAPLUS
CN 2-Pyridineacetamide, 6-[(2-amino-2-oxoethyl)thio]-5-cyano-α,4-diphenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182368 CAPLUS
DN 140:229401
TI Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
IN Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
PA USA
SO U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004043388	A1	20040304	US 2002-234985	20020903
	US 2003165873	A1	20030904	US 2002-91177	20020304
	US 2004266854	A1	20041230	US 2004-820453	20040407
PRAI	US 2001-272932P	P	20010302		
	US 2001-278233P	P	20010323		
	US 2001-329437P	P	20011015		
	US 2002-91177	A2	20020304		
	US 2001-336962P	P	20011203		
	WO 2002-US6677	A2	20020304		
	US 2002-234985	A2	20020903		
	WO 2002-US33052	A2	20021015		
	US 2003-460921P	P	20030407		
	US 2003-531872P	P	20031223		

AB The invention provides comps. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene gycol moiety to dexamethasone, is described.

IT **209410-92-4D**, conjugates **209412-01-1D**, conjugates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 209410-92-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 209412-01-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)


Ph
O
C—NH2
N
CH
Cl
Cl

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:571128 CAPLUS
DN 139:129926
TI Crystal structures of human JNK3 kinase-inhibitor complexes and JNK3 active- and inhibitor-binding sites and applications to drug screening and drug design
IN Xie, Xiaoling
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 244 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003060102	A2	20030724	WO 2003-US899	20030110
	WO 2003060102	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1476840	A2	20041117	EP 2003-708827	20030110
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-348002P	P	20020111		
	WO 2003-US899	W	20030110		

AB The invention relates to crystalline mols. or mol. complexes that comprise binding pockets of c-Jun N-terminal kinase 3 (JNK3) or its homologs. The invention also relates to crystals comprising JNK3 and an inhibitor. Crystal structure and atomic structure coordinates of human JNK3α1 complexes with various inhibitors are provided. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of JNK3 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the mol. or mol. complex. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for, design and optimize compds., including agonists and antagonists, which bind to JNK3 or homologs thereof.

IT **565197-21-9D**, JNK3 complexes
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(crystal structures of JNK3 kinase-inhibitor complexes and JNK3 active- and inhibitor-binding sites and applications to drug screening and drug design)

RN 565197-21-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-5-(2,4-difluorobenzoyl)- (9CI) (CA INDEX NAME)


O
C
N
O
C
NH2
CH
Cl
F
F
Cl

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:802392 CAPLUS
DN 133:350242
TI Preparation of pyrido[1,2-c]pyrimidin-3-ones or 1,2-dihydro-pyrido[1,2-c]pyrimidin-3-ones as inhibitors of p38
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Harrington, Edmund Martin
PA Vertex Pharmaceuticals Incorporated, USA
SO U.S., 28 pp., Cont.-in-part of U.S. 5,945,418.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6147080 — No OOP	A	20001114	US 1997-862925	19970610
US 5945418 — "	A	19990831	US 1997-822373	19970320
CA 2274825	AA	19980625	CA 1997-2274825	19971217
WO 9827098	A1	19980625	WO 1997-US23392	19971217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9856105	A1	19980715	AU 1998-56105	19971217
AU 738000	B2	20010906		
EP 951467	A1	19991027	EP 1997-952517	19971217
EP 951467	B1	20030402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1244867	A	20000216	CN 1997-181382	19971217
BR 9714415	A	20000418	BR 1997-14415	19971217
TR 9902194	T2	20000621	TR 1999-9902194	19971217
NZ 336146	A	20000929	NZ 1997-336146	19971217
JP 2001506266	T2	20010515	JP 1998-527975	19971217
AP 1136	A	20030131	AP 1999-1565	19971217
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
AT 236165	E	20030415	AT 1997-952517	19971217
PT 951467	T	20030829	PT 1997-952517	19971217
EE 4191	B1	20031215	EE 1999-252	19971217
ES 2202658	T3	20040401	ES 1997-952517	19971217
CN 1519240	A	20040811	CN 2003-2003158796	19971217
SK 284578	B6	20050701	SK 1999-805	19971217
TW 521071	B	20030221	TW 1997-86119152	19971218
NO 9902960	A	19990817	NO 1999-2960	19990617
NO 315047	B1	20030630		
BG 64533	B1	20050630	BG 1999-103575	19990713
HK 1023340	A1	20031224	HK 2000-102323	20000418
US 2005009844	A1	20050113	US 2003-622320	20030717
PRAI US 1996-34288P	P	19961218		
US 1997-822373	A2	19970320		
US 1997-862925	A	19970610		
WO 1997-US23392	W	19971217		
US 1999-336266	A1	19990614		

OS MARPAT 133:350242

Appl.

AB The title compds. [I or II; Q1, Q2 = (un)substituted Ph, 5-6 membered aromatic heterocyclic ring systems having one N atom; X = S, O, SO2, etc.; Y = C; R = H, alkyl; A = N, CH, C(alkyl), C(alkenyl), C(alkynyl); n = 1; R1 = H, alkyl, OH. O(alkyl)], useful as inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli, were prepared E.g., a multi-step synthesis of the compound I [Q1, Q2 = Ph; X = S; Y = C; R = H; A = N; n = 1; R1 = H] which showed IC50 of > 20 μM against p38 binding, was given.

IT **209410-92-4P 209412-01-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrido[1,2-c]pyrimidin-3-ones or 1,2-dihydro-pyrido[1,2-c]pyrimidin-3-ones as inhibitors of p38)

RN 209410-92-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 209412-01-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:736658 CAPLUS
DN 131:336949
TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.
IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958502	A1	19991118	WO 1999-US10291	19990511
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331460	AA	19991118	CA 1999-2331460	19990511
	AU 9937923	A1	19991129	AU 1999-37923	19990511
	AU 764047	B2	20030807		
	EP 1077943	A1	20010228	EP 1999-920427	19990511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	TR 200003300	T2	20010321	TR 2000-200003300	19990511
	BR 9911786	A	20010403	BR 1999-11786	19990511
	EE 200000610	A	20020415	EE 2000-610	19990511
	NZ 508653	A	20030725	NZ 1999-508653	19990511
	NO 2000005673	A	20010110	NO 2000-5673	20001110
	ZA 2000006987	A	20011126	ZA 2000-6987	20001128
	BG 105031	A	20011031	BG 2000-105031	20001207
	US 2002019393	A1	20020214	US 2000-746722	20001221
⇒	US 6632945	B2	20031014		
	US 2004132729	A1	20040708	US 2003-638126	20030808
PRAI	US 1998-85053P	P	19980511		
	US 1999-127626P	P	19990401		
	US 1999-129099P	P	19990413		
	WO 1999-US10291	W	19990511		
	US 2000-746722	A3	20001221		

OS MARPAT 131:336949
AB Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicyclyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U = R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.; R2 = H, (substituted) alkyl, alkenyl], were prepared Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (preparation given), Tl2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed by aqueous acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compound (II). Tested title compds. inhibited recombinant p38 kinase with

IC50 = 0.02-0.56 μM.

IT **250122-82-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinylarylureas and related compds. as inhibitors of p38 kinase)

RN 250122-82-8 CAPLUS

CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-α-(2,6-dichlorophenyl)-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



IT **250123-29-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridinylarylureas and related compds. as inhibitors of p38 kinase)

RN 250123-29-6 CAPLUS

CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-α-(2,6-dichlorophenyl)-4-[[(methylsulfonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

prepared Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z = pyridazine-3,6-diyl) which was hydrolized to the amide and the product cyclized to give title compound II.

IT **209410-92-4P 209410-98-0P 209410-99-1P**
209411-00-7P 209411-01-8P 209411-02-9P
209411-03-0P 209411-04-1P 209411-05-2P
209411-06-3P 209411-07-4P 209411-08-5P
209411-09-6P 209411-10-9P 209411-11-0P
209411-12-1P 209411-13-2P 209411-14-3P
209411-15-4P 209411-16-5P 209411-17-6P
209411-18-7P 209411-19-8P 209411-20-1P
209411-21-2P 209411-22-3P 209411-23-4P
209411-24-5P 209411-25-6P 209411-26-7P
209411-27-8P 209411-28-9P 209411-29-0P
209411-30-3P 209411-31-4P 209411-32-5P
209411-33-6P 209411-34-7P 209411-35-8P
209411-36-9P 209411-37-0P 209411-38-1P
209411-39-2P 209411-40-5P 209411-41-6P
209411-42-7P 209411-43-8P 209411-44-9P
209411-45-0P 209411-46-1P 209411-47-2P
209411-48-3P 209411-49-4P 209411-50-7P
209411-51-8P 209411-52-9P 209411-53-0P
209411-54-1P 209411-55-2P 209411-56-3P
209411-57-4P 209411-58-5P 209411-59-6P
209411-60-9P 209411-61-0P 209411-62-1P
209411-63-2P 209411-64-3P 209411-65-4P
209411-66-5P 209411-67-6P 209411-68-7P
209411-69-8P 209411-70-1P 209411-71-2P
209411-72-3P 209411-74-5P 209411-75-6P
209411-76-7P 209411-77-8P 209411-78-9P
209411-79-0P 209411-80-3P 209411-81-4P
209411-82-5P 209411-83-6P 209411-84-7P
209411-85-8P 209411-86-9P 209411-87-0P
209411-88-1P 209411-89-2P 209412-01-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors)

RN 209410-92-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 209410-98-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)-

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:424256 CAPLUS
DN 129:81749
TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English

Appl PCT

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945418 } No ODP	A	19990831	US 1997-822373	19970320
	US 6147080 } No ODP	A	20001114	US 1997-862925	19970610
	CA 2274825	AA	19980625	CA 1997-2274825	19971217
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	AU 738000	B2	20010906		
	EP 951467	A1	19991027	EP 1997-952517	19971217
	EP 951467	B1	20030402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	BR 9714415	A	20000418	BR 1997-14415	19971217
	NZ 336146	A	20000929	NZ 1997-336146	19971217
	JP 2001506266	T2	20010515	JP 1998-527975	19971217
	AP 1136	A	20030131	AP 1999-1565	19971217
	W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
	AT 236165	E	20030415	AT 1997-952517	19971217
	EE 4191	B1	20031215	EE 1999-252	19971217
	SK 284578	B6	20050701	SK 1999-805	19971217
	US 6608060 No ODP	B1	20030819	US 1999-336266	19990614
	NO 9902960	A	19990817	NO 1999-2960	19990617
	NO 315047	B1	20030630		
	HK 1023340	A1	20031224	HK 2000-102323	20000418
	US 2005009844	A1	20050113	US 2003-622320	20030717
PRAI	US 1996-34288P	P	19961218		
	US 1997-822373	A	19970320		
	US 1997-862925	A2	19970610		
	WO 1997-US23392	W	19971217		
	US 1999-336266	A1	19990614		

OS MARPAT 129:81749
AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were

(9CI) (CA INDEX NAME)



RN 209410-99-1 CAPLUS
CN 2-Pyridineacetamide, 5-benzoyl-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-00-7 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-01-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-02-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-03-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-04-1 CAPLUS
CN 2-Pyridineacetamide, 6-(4-chlorophenyl)-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-05-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-06-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-07-4 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-4-fluorophenyl)-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-08-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-09-6 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-10-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[(hydroxyimino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-11-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 209411-12-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-13-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-14-3 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chlorophenyl)-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-15-4 CAPLUS
CN Benzoic acid, 4-[6-[2-amino-1-(2,6-dichlorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-16-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-17-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-18-7 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-19-8 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 209411-20-1 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-21-2 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-formylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-22-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-23-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-24-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-methoxyphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-25-6 CAPLUS
CN 2-Pyridineacetamide, 6-(2,4-dichlorophenyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-26-7 CAPLUS
CN 2-Pyridineacetamide, 6-(5-chloro-2-thienyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-27-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-formylphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-28-9 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-29-0 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-30-3 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-31-4 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-32-5 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-33-6 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-34-7 CAPLUS
CN Benzoic acid, 4-[6-[2-amino-1-(2-chloro-6-fluorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-35-8 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-formylphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-36-9 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-thienyl)-
(9CI) (CA INDEX NAME)



RN 209411-37-0 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-thienyl)-
(9CI) (CA INDEX NAME)



RN 209411-38-1 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-39-2 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-40-5 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-41-6 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-42-7 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(5-chloro-2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-43-8 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-44-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,5-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-45-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-46-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[[(2-hydroxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-47-2 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-48-3 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-49-4 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(2-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-50-7 CAPLUS
CN 2-Pyridineacetamide, 6-(2-benzofuranyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-51-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-52-9 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-53-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-54-1 CAPLUS
CN 2-Pyridineacetamide, α-(4-amino-2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-55-2 CAPLUS
CN 2-Pyridineacetamide, 6-benzo[b]thien-2-yl-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-56-3 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(3-formyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 209411-57-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[(phenylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-58-5 CAPLUS
CN 2-Pyridineacetamide, 6-[2-[[(2-aminoethyl)amino]methyl]phenyl]-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-59-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-[[(2,3-dihydroxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-60-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-61-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-difluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-62-1 CAPLUS
CN 2-Pyridineacetamide, α-(2-chloro-6-fluorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-63-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



RN 209411-64-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-2-
methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-65-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-66-5 CAPLUS
CN 2-Pyridineacetamide, 6-(2,3-dichlorophenyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-67-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-68-7 CAPLUS
CN 2-Pyridineacetamide, 6-(2-chlorophenyl)-α-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-69-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-70-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-71-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-72-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-74-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-75-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-76-7 CAPLUS
CN 2-Pyridineacetamide, 6-[3,5-bis(trifluoromethyl)phenyl]-α-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-77-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-78-9 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[3-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-79-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dimethylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-80-3 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-81-4 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-82-5 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-[(methoxymethoxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-83-6 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-84-7 CAPLUS

CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-85-8 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-86-9 CAPLUS
CN 2-Pyridineacetamide, α-(6-chloro-1,3-benzodioxol-5-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-87-0 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-[4-fluoro-2-

(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-88-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-89-2 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209412-01-1 CAPLUS
CN 2-Pyridineacetamide, α-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 16:37:36 ON 30 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 16:37:41 ON 30 AUG 2005
L1                STRUCTURE UPLOADED
L2              0 S L1 SSS SAM
L3                STRUCTURE UPLOADED
L4              6 S L3 SSS SAM
L5             97 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 16:48:09 ON 30 AUG 2005
L6              6 S L5

     FILE 'CAOLD' ENTERED AT 16:48:38 ON 30 AUG 2005

=> s l5
L7              0 L5

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.43     198.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.38

STN INTERNATIONAL LOGOFF AT 16:48:51 ON 30 AUG 2005
```